There is no cure for Sjögren’s syndrome. It is a chronic autoimmune condition, and current treatments focus entirely on managing symptoms and preventing complications. The core reason a cure remains out of reach is that by the time most people are diagnosed, the immune system has already caused irreversible damage to the moisture-producing glands. Once that gland architecture is destroyed, it cannot be restored.
That said, the treatment landscape is not static. Several therapies can meaningfully improve quality of life, and a new class of drugs targeting the immune cells responsible for the disease recently showed promising results in late-stage clinical trials.
Why Gland Damage Can’t Be Reversed
Sjögren’s syndrome occurs when the immune system attacks the glands that produce tears and saliva. Over time, clusters of immune cells infiltrate these glands and destroy the tissue that secretes moisture. This process typically happens gradually and silently, often for years before dryness becomes noticeable enough to prompt a doctor’s visit.
By the time someone develops the hallmark symptoms of persistent dry eyes and dry mouth, substantial glandular destruction has usually already occurred. The damaged tissue doesn’t regenerate. This is the fundamental barrier to a cure: even if you could completely shut down the autoimmune attack, the glands that have already been destroyed won’t grow back. Treatment can protect remaining gland function and relieve symptoms, but it cannot undo the damage that’s already done.
Who Gets Sjögren’s Syndrome
Sjögren’s overwhelmingly affects women, with a female-to-male ratio of about 9 to 1. It most commonly appears in middle age, though it can develop at any point in adulthood. The estimated prevalence is roughly 0.5% of the population. It can occur on its own (primary Sjögren’s) or alongside another autoimmune condition like rheumatoid arthritis or lupus (secondary Sjögren’s).
Managing Dry Mouth
Dry mouth is more than an annoyance. It increases the risk of tooth decay, gum disease, and oral infections because saliva plays a critical protective role in the mouth. For mild dryness, sugar-free lozenges, frequent water sipping, and saliva substitutes can help.
When those aren’t enough, prescription medications can stimulate whatever functional gland tissue remains. Pilocarpine (brand name Salagen) is the most commonly prescribed option, typically taken three or four times a day. It works by directly stimulating the glands to produce more saliva, which can improve chewing, tasting, swallowing, and the ability to speak without constantly sipping water. A similar medication, cevimeline, works through the same basic mechanism. Neither drug repairs the glands, but both can coax more output from the tissue that’s still intact.
Managing Dry Eyes
Artificial tears are the first line of defense for dry eyes, and many people with Sjögren’s use them multiple times a day. Preservative-free formulations are generally preferred for frequent use because preservatives can irritate already-sensitive eyes over time.
For moderate to severe dryness that doesn’t respond well to artificial tears alone, prescription eye drops that reduce inflammation on the surface of the eye can help. These drops work by calming the localized immune response that contributes to tear film instability. Studies in Sjögren’s patients show significant improvements in corneal surface health and tear stability after about two months of treatment. The results are similar whether the dry eye is caused by Sjögren’s or other conditions. Some people also benefit from punctal plugs, tiny inserts placed in the tear ducts to keep tears on the eye surface longer.
Treating the Whole-Body Disease
Sjögren’s is not just about dryness. Fatigue is one of the most common and debilitating symptoms, often described as a deep, unrelenting exhaustion that doesn’t improve with rest. Joint pain, skin rashes, and brain fog are also frequent. About 25% of patients develop internal organ involvement, including lung, kidney, or nervous system complications. Roughly 16% experience some form of pulmonary involvement, which carries higher mortality risk and significantly lower quality of life.
Hydroxychloroquine, an anti-inflammatory drug widely used in lupus, is frequently prescribed for Sjögren’s. However, the evidence for its effectiveness is surprisingly weak. A systematic review and meta-analysis found no significant improvement in fatigue, joint symptoms, eye involvement, or lung, neurological, or kidney complications compared to not taking the drug. Despite this, some rheumatologists still prescribe it based on individual patient response, particularly for joint pain and fatigue, where the data is mixed rather than definitively negative.
For severe cases involving organ damage, stronger immune-suppressing medications are used. Rituximab, a drug that destroys a type of immune cell called B cells, is sometimes used for patients with serious systemic disease or lymphoma. Meta-analyses show it can reduce pain scores, lower certain antibody levels, and deplete the B cells driving the disease. However, it does not improve gland function (neither tear production nor saliva flow) and doesn’t significantly reduce overall disease activity scores. It’s generally reserved for refractory cases where other treatments have failed.
The Lymphoma Risk
The most serious long-term complication of Sjögren’s is an elevated risk of non-Hodgkin lymphoma, a type of blood cancer that develops in the very B cells that are chronically activated by the disease. A single-center retrospective study found the risk was about 30 times higher than in the general population. This doesn’t mean most people with Sjögren’s will develop lymphoma, but it does mean that regular monitoring with blood work and attention to new symptoms like unexplained swelling of salivary glands, night sweats, or rapid weight loss is important.
What’s Closest to Changing the Outlook
The most significant recent development is ianalumab, a drug with a dual mechanism: it both destroys B cells and blocks a protein that helps B cells survive and multiply. Two large Phase 3 clinical trials, called NEPTUNUS-1 and NEPTUNUS-2, recently met their primary endpoints, showing significant improvement in disease activity in Sjögren’s patients. These are the first replicate Phase 3 trials in Sjögren’s to achieve this milestone.
Ianalumab is not a cure. It targets the immune process driving the disease rather than restoring damaged glands. But if approved, it would be the first drug specifically validated for reducing Sjögren’s disease activity in large, rigorous trials. For a condition that has relied almost entirely on symptom management and repurposed drugs from other autoimmune diseases, that would represent a meaningful shift in treatment. Whether it can prevent gland destruction if given early enough, before significant damage accumulates, is a question that remains unanswered.